Expression and secretion of human glucocerebrosidase mediated by recombinant lentivirus vectors in vitro and in vivo: Implications for gene therapy of Gaucher disease

Biochemical and Biophysical Research Communications

Volumn 318, Issue 2, 2004, Pages 381-390

  Kim, Eun Young ^a,b   Hong, Young Bin ^a   Lai, Zhennan ^c   Kim, Hyon J ^d   Cho, Youl Hee ^b   Brady, Roscoe O ^c   Jung, Sung Chul ^a  

^a Korea National Institute of Health   (South Korea)

^b Hanyang University   (South Korea)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^d Ajou University School of Medicine   (South Korea)

Author keywords

Gaucher disease; Gene therapy; Glucocerebrosidase; Lentivirus; Liver; Mouse

Indexed keywords

GLUCOSYLCERAMIDASE; LENTIVIRUS VECTOR;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOCYTOSIS; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME RELEASE; EXPRESSION VECTOR; FIBROBLAST; GAUCHER DISEASE; GENE TRANSFER; GENETIC TRANSDUCTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE DISTRIBUTION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELL LINE; CELLS, CULTURED; ENDOCYTOSIS; FIBROBLASTS; GAUCHER DISEASE; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; GLUCOSYLCERAMIDASE; HELA CELLS; HUMANS; INJECTIONS, INTRAVENOUS; LENTIVIRUS; MICE; MICE, INBRED C57BL; PORTAL VEIN; TAIL; TISSUE DISTRIBUTION; TRANSDUCTION, GENETIC;

HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS;

EID: 2142713043     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.04.040     Document Type: Article

References (46)

1. Brady R.O., Kanfer J.N., Bradley R.M., Shapiro D. Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. J. Clin. Invest. 45:1966;1112-1115
2. Beutler E., Grabowski G.A. Gaucher disease. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The Metabolic and Molecular Bases of Inherited Disease. 2001;3635-3668 McGraw-Hill, New York
3. Brady R.O., Barton N.W., Grabowski G.A. The role of neurogenetics in Gaucher disease. Arch. Neurol. 50:1993;1212-1224
4. Kornfeld S., Mellman I. The biogenesis of lysosomes. Annu. Rev. Cell Biol. 5:1989;483-525
5. Barton N.W., Furbish F.S., Murray G.J., Garfield M., Brady R.O. Therapeutic response to intravenous infusion of glucocerebrosidase in a patient with Gaucher disease. Proc. Natl. Acad. Sci. USA. 87:1990;1913-1916
6. Barton N.W., Brady R.O., Dambrosia J.M., Di Bisceglie A.M., Doppelt S.H., Hill S.C., Mankin H.J., Murray G.J., Parker R.I., Argoff C.E., Grewal R.P., Yu K.T. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher disease. N. Engl. J. Med. 324:1991;1464-1470
7. Grabowski G.A., Barton N.W., Pastores G., Dambrosia J.M., Banerjee T.K., McKee M.A., Parker C., Schiffmann R., Hill S.C., Brady R.O. Enzyme therapy in Gaucher disease Type 1: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann. Int. Med. 122:1995;33-39
8. Cox T., Lachmann R., Hollak C., Aerts J., van Weely S., Hrebicek M., Platt F., Butters T., Dwek R., Moyses C., Gow I., Elstein D., Zimran A.T. Novel oral treatment of Gaucher disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet. 355:2000;1481-1485
9. Pink J.K., Correll P.H., Perry L.K., Brady R.O., Karlsson S. Correction of glucocerebrosidase deficiency after retroviral-mediated gene transfer into hematopoietic progenitor cells from patients with Gaucher disease. Proc. Natl. Acad. Sci. USA. 87:1990;2334-2338
10. Kohn D.B., Nolta J.A., Weinthal J., Bahner I., Yu X.J., Lilley J., Crooks G.M. Toward gene therapy for Gaucher disease. Hum. Gene Ther. 2:1991;101-105
11. Nolta J.A., Sender L.S., Barranger J.A., Kohn D.B. Expression of human glucocerebrosidase in murine long-term bone marrow cultures after retroviral vector-mediated transfer. Blood. 75:1990;787-798
12. Correll P.H., Colilla S., Dave H.P., Karlsson S. High levels of human glucocerebrosidase activity in macrophages of long-term reconstituted mice after retroviral infection of hematopoietic stem cells. Blood. 80:1992;331-336
13. Novelli E.M., Barranger J.A. Gene therapy for lysosomal storage disorders. Expert Opin. Biol. Ther. 1:2001;857-867
14. Grabowski G.A., Barton N.W., Pastores G., Dambrosia J.M., Banerjee T.K., McKee M.A., Parker C., Schiffmann R., Hill S.C., Brady R.O. Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. Hum. Gene Ther. 92:1998;2629-2640
15. Marshall J., McEachern K.A., Cavanagh J.A., Nietupski J.B., Budzinski T.L., Ziegler R.J., Yew N.S., Sullivan J., Scaria A., Rooijen N., Barranger J.A., Cheng S.H. Demonstration of feasibility of in vivo gene therapy for Gaucher disease using a chemically induced mouse model. Mol. Ther. 6:2002;179-189
16. Bukrinsky M.I., Haggerty S., Dempsey M.P., Sharova N., Adzhubel A., Spitz L., Lewis P., Goldfarb D., Emerman M., Stevenson M. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-diving cells. Nature. 365:1993;666-669
17. Costello E., Munoz M., Buetti E., Meylan P.R., Diggelmann H., Thali M.E. Gene transfer into stimulated and unstimulated T lymphocytes by HIV-1-derived lentiviral vectors. Gene Ther. 7:2000;596-604
18. Miyoshi H., Smith K.A., Mosierm D.E., Verma I.M., Torbett B.E. Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science. 283:1999;682-686
19. Schroers R., Sinha I., Segall H., Schmidt-Wolf I.G., Rooney C.M., Brenner M.K., Sutton R.E., Chen S.Y. Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. Mol. Ther. 1:2000;171-179
20. Naldini L., Blomer U., Gage F.H., Trono D., Verma I.M. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains infected with a lentiviral vector. Proc. Natl. Acad. Sci. USA. 93:1996;11382-11388
21. Zhennan L., Brady R.O. Gene transfer into the central nervous system in vivo using a recombinant lentivirus vector. J. Neurosci. Res. 67:2002;363-371
22. Kafri T., Blomer U., Peterson D.A., Gage F.H., Verma I.M. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat. Genet. 17:1997;314-317
23. Mochizuki H., Schwartz J.P., Tanaka K., Brady R.O., Reiser J. High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells. J. Virol. 72:1998;8873-8883
24. Lai Z., Han I., Zirzow G., Brady R.O., Reiser J. Intercellular delivery of a herpes simplex virus VP22 fusion protein from cells infected with lentiviral vectors. Proc. Natl. Acad. Sci. USA. 97:2000;11297-11302
25. Pear W.S., Nolan G.P., Scott M.L., Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA. 90:1993;8392-8396
26. Villani G.R.D., Follenzi A., Vanacore B., Domenico C.D., Naldini L., Natale P.D. Correction of mucopolysaccharidosis type IIIb fibroblasts by lentivirus vector-mediated gene transfer. Biochem. J. 364:2002;747-753
27. Dinur T., Grabowski G.A., Desnick R.J., Gatt S. Synthesis of a fluorescent derivative of glucosyl ceramide for the sensitive determination of glucocerebrosidase activity. Anal. Biochem. 136:1984;223-234
28. Chun T.W., Stuyver L., Mizell S.B., Ehler L.A., Mican J.A.M., Baseler M., Lloyd A.L., Nowak M.A., Fauci A.S. Presence of an indicible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA. 94:1997;13193-13197
29. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., Verma I.M., Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 272:1996;263-267
30. Nguyen T.H., Oberholzer J., Birraux J., Majno P., Morel P., Trono D. Highly efficient lentiviral vector-mediated transduction of nondividing, fully reimplantable primary hepatocytes. Mol. Ther. 6:2002;199-209
31. Doebber T.W., Wu M.S., Bugianesi R.L., Ponpipom M.M., Furbish F.S., Barranger J.A., Brady R.O., Shen T.Y. Enhanced macrophage uptake of synthetically glycosylated human placental beta-glucocerebrosidase. J. Biol. Chem. 257:1982;2193-2199
32. Furbish F.S., Steer C.J., Krett N.L., Barranger J.A. Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. Biochim. Biophys. Acta. 673:1981;425-434
33. Takasaki S., Murray G.J., Furbish F.S., Brady R.O., Barranger J.A., Kobata A. Structure of the N-asparagine-linked oligosaccharide units of human placental beta-glucocerebrosidase. J. Biol. Chem. 259:1984;10112-10117
34. Erickson A.H., Ginns E.I., Barranger J.A. Biosynthesis of the lysosomal enzyme glucocerebrosidase. J. Biol. Chem. 260:1985;14319-14324
35. Tybulewiez V.L.J., Trembly M.L., LaMarea M.E., Willemsen P., Stubblefield B.K., Winfield S., Zablocka B., Sidransky E., Martin B.M., Huang S.P., Mintzer K.N., Westphal H., Mulligan R.O., Ginns E.I. Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene. Nature. 357:1992;407-410
36. Liu Y., Suzuki K., Reed J.D., Grinberg A., Westphal H., Hoffmann A., Doring T., Sandhoff K., Proia R.L.Y. Mice with type 2 and 3 Gaucher disease point mutations generated by a single insertion mutagenesis procedure (SIMP). Proc. Natl. Acad. Sci. USA. 95:1998;2503-2508
37. Tsui L.V., Kelly M., Zayek N., Rojas V., Ho K., Ge Y., Moskalenko M., Mondesire J., Davis J., Roey M.V., Dull T., McArthur J.G. Production of human clotting factor IX without toxicity in mice after vascular delivery of a lentiviral vector. Nat. Biotechnol. 20:2002;53-57
38. Follenzi A., Sabatino G., Lombardo A., Boccaccio C., Naldini L. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum. Gene Ther. 13:2002;243-260
39. Park F., Ohashi K., Kay M.A. The effect of age on hepatic gene transfer with self-inactivating lentiviral vectors in vivo. Mol. Ther. 8:2003;314-323
40. Mistry P.K., Wraight E.P., Cox T.M. Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease. Lancet. 348:1996;1555-1559
41. Li L., Olvera J.M., Yoder K.E., Mitchell R.S., Butler S.L., Lieber M., Martin S.L., Bushman F.D. Role of the non-homologous DNA end joining pathway in the early steps of retroviral infection. EMBO J. 20:2001;3272-3281
42. Butler S.L., Hansen M.S., Bushman F.D. A quantitative assay for HIV cDNA integration in vivo. Nat. Med. 7:2001;631-634
43. Zennou V., Petit C., Guetard D., Nerhbass U., Montagnier L., Charneau P. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell. 101:2000;173-185
44. Bell P., Montaner L.J., Maul G.G. Accumulation and intranuclear distribution of unintegrated human immunodeficiency virus type 1 DNA. J. Virol. 75:2001;7683-7691
45. Mitchell R., Chiang C.Y., Berry C., Bushman F. Global analysis of cellular transcription following infection with an HIV-based vector. Mol. Ther. 8:2003;674-687
46. Pan D., Gunther R., Duan W., Wendell S., Kaemmerer W., Kafri T., Verma I.M., Whitley C.B. Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow. Mol. Ther. 6:2002;19-29